<DOC>
	<DOCNO>NCT00326950</DOCNO>
	<brief_summary>The primary objective study determine dose limit toxicity maximum tolerate dose E7389 patient solid tumor . The secondary objective investigate pharmacokinetics , safety , estimate recommend dose , anti-tumor effect ( evaluable case ) E7389 patient solid tumor .</brief_summary>
	<brief_title>Phase I Clinical Study E7389</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Patients histologically cytologically confirm solid tumor . 2 . Patients progress follow standard therapy treatment option . 3 . Patients age 2074 give inform consent . 4 . Patients performance status ( PS ) Eastern Cooperative Oncology Group ( ECOG ) 0 1 . 5 . Patients stay hospital start study drug treatment 2 week first cycle . 6 . Patients adequate function major organ ( bone marrow , liver , kidney lung ) : ( 1 ) Neutrophil count 1,500/mm3 ( 2 ) Platelet count 100,000/mm3 ( 3 ) Hemoglobin 9.0 g/dL ( 4 ) Aspartate aminotransferase [ AST ] 2.5 time upper limit normal ( ULN ) institute , unless relate liver involvement tumor , case 5.0 time ULN ( 5 ) Alanine aminotransferase [ ALT ] 2.5 time ULN institute , unless relate liver involvement tumor , case 5.0 time ULN ( 6 ) Total bilirubin 1.5 time ULN institute ( 7 ) Serum creatinine 1.5 time ULN institute ( 8 ) Pulse oximeter oxygen saturation 90 % 7 . Patients adverse drug reaction ( exclude alopecia , etc . ) cause prior therapy could influence safety evaluation study drug . The withdrawal period require completion prior therapy start study drug therapy follow : 1 . Chemotherapy ( exclude oral 5FU molecular target drug ) , surgical therapy , study drug : 4 week 2 . Nitrosourea agent , mitomycin C : 6 week 3 . Radiotherapy , endocrinotherapy , immunotherapy , oral 5FU , molecular target drug , blood transfusion , blood product , GCSF hematopoietic factor : 2 week 8 . Patients give write informed consent . 9 . Patients expect survival long 3 month start study drug therapy . Exclusion criterion : 1 . Patients systemic infection fever ( 38Â°C ) . 2 . Patients large amount pleural effusion , ascites pericardial fluid require drainage . 3 . Patients brain metastasis clinical symptom . 4 . Patients serious complication : ( 1 ) Patients uncontrollable cardiac disease ischemic heart disease arrhythmia level severity need treat ( exclude leave ventricular hypertrophy , mild leave ventricular volume overload mild right leg block accompany hypertension ) ( 2 ) Patients myocardial infarction within 6 month prior study entry ( 3 ) Patients complication hepatic cirrhosis ( 4 ) Patients interstitial pneumonia pulmonary fibrosis ( 5 ) Patients bleed tendency 5 . Women pregnant breastfeeding , premenopausal woman childbearing potential . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Premenopausal woman childbearing potential either positive pregnancy test screening pregnancy test , agree use adequate measure contraception . 6 . Fertile men willing use contraception fertile men female partner willing use contraception . 7 . Patients test positive human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) antibody , hepatitis B virus surface antigen ( HBsAg ) . 8 . Patients need continuous systemic steroid therapy study period . 9 . Patients need continuous use phenytoin , carbamazepine , rifampicin and/or barbiturate induces cytochrome P450 ( CYP3A4 ) , drugmetabolizing enzyme , study period . 10 . Patients receive extensive radiation therapy ( 30 % bone marrow ) . 11 . Patients refuse receive supportive therapy blood transfusion suppress bone marrow . 12 . Patients participate clinical study . 13 . Patients investigator subinvestigator judge inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumors</keyword>
	<keyword>Phase I</keyword>
	<keyword>E7389</keyword>
</DOC>